arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2021-27-3-291-299arthyper-2055Research ArticleОБЗОРREVIEWМеханизмы антигипертензивного действия бета-адреноблокаторовMechanisms of beta-blockers antihypertensive actionКулешоваЭ. В.KuleshovaE. V.

Кулешова Эльвира Владимировна — доктор медицинских наук, профессор, главный научный сотрудник отдела ишемической болезни сердца Института сердечно-сосудистых заболеваний

Санкт-Петербург

Elvira V. Kuleshova, MD, PhD, DSc, Chief  Researcher, Department of Ischemic Heart Disease, Institute of Cardiovascular Diseases

St Petersburg

kuleshova@yandex.ruКузьменкоН. В.KuzmenkoN. V.

Кузьменко Наталия Владимировна — кандидат биологических наук, старший научный сотрудник отдела экспериментальной физиологии и фармакологии Центра доклинических и трансляционных исследований ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России, младший научный сотрудник лаборатории биофизики кровообращения Научно-образовательного института биомедицины ГБОУ ВПО «ПСПбГМУ им. акад. И. П. Павлова» Минздрава России

пр. Пархоменко, д. 15, Санкт-Петербург, 194156

Natalia V. Kuzmenko, PhD in Biology, Senior Researcher, Department of Experimental Physiology and Pharmacology, Preclinical and Translational Research Centre, Almazov National Medical Research Centre, Senior Researcher of Blood Circulation Biophysics  Laboratory, Research Educational Institute of Biomedicine, Pavlov University

15 Parkhomenko avenue, St Petersburg, 194156

kuzmenko_nv@almazovcentre.ruПлиссМ. Г.PlissM. G.

Плисс Михаил Геннадиевич — кандидат медицинских наук, заведующий отделом экспериментальной физиологии и фармакологии Центра доклинических и трансляционных исследований ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России, заведующий лабораторией биофизики кровообращения Научно-образовательного института биомедицины ГБОУ ВПО «ПСПбГМУ им. акад. И. П. Павлова» Минздрава России

Санкт-Петербург

Mikhail G. Pliss, MD, PhD, Head, Department of Experimental Physiology and Pharmacology, Preclinical and Translational Research Centre, Almazov National Medical Research Centre, Head, Biophysics of Blood Circulation Laboratory, Research Educational Institute of Biomedicine, Pavlov University

St Petersburg

pliss@niiekf.ruЦырлинВ. А.TsyrlinV. A.

Цырлин Виталий Александрович — доктор медицинских наук, профессор, главный научный сотрудник отдела экспериментальной физиологии и фармакологии Центра доклинических и трансляционных исследований

Санкт-Петербург

Vitaliy A. Tsyrlin, MD, PhD, DSc, Professor, Chief Researcher, Department of Experimental Physiology and Pharmacology of Preclinical and Translational Research Centre

St Petersburg

tsyrlinva@mail.ruФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research CentreRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации; Государственное бюджетное образовательное учреждение высшего профессионального образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research Centre; Pavlov UniversityRussian Federation202123042021273291299Copyright © Кулешова Э.В., Кузьменко Н.В., Плисс М.Г., Цырлин В.А., 20212021Кулешова Э.В., Кузьменко Н.В., Плисс М.Г., Цырлин В.А.Kuleshova E.V., Kuzmenko N.V., Pliss M.G., Tsyrlin V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/2055

Настоящая статья представляет собой анализ данных о механизмах антигипертензивного эффекта блокаторов β-адренергических рецепторов. Описывается эффективность кардиотропного действия препаратов для снижения повышенного артериального давления (АД) при кратковременном и длительном назначении соединений, возможность влияния блокаторов на активность ренина плазмы. Рассматривается влияние β-адреноблокаторов на центральные механизмы регуляции кровообращения. Представлены сведения о влиянии β-адреноблокаторов на миогенные механизмы регуляции сосудистого тонуса. Анализируются возможности влияния β-адреноблокаторов на эндотелийзависимую гиперполяризацию гладких мышц резистивных артерий, нарушения NO-цГМФ-пути и блокады токов Ca2+-каналов как факторов, обеспечивающих расширение резистивных сосудов и снижение повышенного АД.

This article presents an analysis of data on the mechanisms of antihypertensive effect of β-adrenergic receptor blockers. The article describes the effectiveness of cardiotropic action of drugs to reduce high blood pressure (BP) with short-term and long-term action of compounds, the effect of blockers on the activity of plasma renin. The influence of β-blockers on the central mechanisms of blood circulation regulation is considered. Information on the effect of β-blockers on myogenic mechanisms of vascular tone regulation is presented. The possibilities of blockade of β-adrenergic receptors of endothelium-dependent hyperpolarization of smooth muscles of resistive arteries, violation of the NO-cGMP pathway and blockade of Ca2+ channel currents as factors providing expansion of resistive vessels and reduction of high BP are analyzed.

артериальная гипертензияβ-адреноблокаторыэндотелийзависимая гиперполяризацияблокады токов Ca2+-каналовминутный объем кровообращенияhypertensionβ-blockersendothelium-dependent hyperpolarizationcurrent blockages of Ca2+ channelscardiac outputReferencesAhlquist RP. A study of the adrenotropic receptors. Am J Physiol. 1948;153(3):586–600. doi:10.1152/ajplegacyAhlquist RP. A study of the adrenotropic receptors. Am J Physiol. 1948;153(3):586–600. doi:10.1152/ajplegacyPrichard BN, Gillam PM. Use of propranolol (inderal) in treatment of hypertension. Br Med J. 1964;2(5411):725–727. doi:10.1136/bmj.2.5411.725Prichard BN, Gillam PM. Use of propranolol (inderal) in treatment of hypertension. Br Med J. 1964;2(5411):725–727. doi:10.1136/bmj.2.5411.725Вальдман А. В., Алмазов В. А., Цырлин В. А. Клиническая нейрофармакология гипотензивных средств. М.: Медицина, 1978. 271 с.Valdman AV, Almazov VA, Tsyrlin VA. Clinical neuropharmacology of hypotensive agents. M.: Medicine, 1978. 271 p. In Russian.Перепеч Н.Б., Шурыгина В.Д. Место β-адреноблокаторов в фармакотерапии артериальной гипертензии. Обзор литературы. Вестник СПбГУ. 2014;11(1):76–86.Perepech NB, Shurygina VD. The place of β-blockers in the pharmacotherapy of arterial hypertension. Literature review. Vestnik SPbGU. 2014;11(1):76–86. In Russian.Шляхто Е. В., Конради А. О., Цырлин В. А. Вегетативная нервная система и артериальная гипертензия. СПб.: Медицинское издательство, 2008. 312 с.Shlyakhto EV, Konradi AO, Tsyrlin VA. Autonomic nervous system and arterial hypertension. St Petersburg: Medical Publishing house, 2008. 312 p. In Russian.Алмазов В. А., Цырлин В. А., Шляхто Е. В., Маслова Н. П. Антигипертензивные препараты. СПб.: Издательство СПбГМУ, 1997. 232 с.Almazov VA, Tsyrlin VA, Shlyakhto EV, Maslova NP. Antihypertensive drugs. St Petersburg: SPbGMU publishing house, 1997. 232 p. In Russian.Franciosa JA, Freis ED. Normal cardiac output during β blockade with timolol in hypertensive patients. Clin Pharmacol Ther. 1975;18(2):158–164.Franciosa JA, Freis ED. Normal cardiac output during β blockade with timolol in hypertensive patients. Clin Pharmacol Ther. 1975;18(2):158–164.Colfer HT, Cottier C, Sanchez R, Julius S. Role of cardiac factors in the initial hypotensive action by β-adrenoreceptor blocking agents. Hypertension. 1984;6(2 Pt 1):145–151.Colfer HT, Cottier C, Sanchez R, Julius S. Role of cardiac factors in the initial hypotensive action by β-adrenoreceptor blocking agents. Hypertension. 1984;6(2 Pt 1):145–151.Sybertz EJ, Watkins RW. Preclinical pharmacologic properties of dilevalol, an antihypertensive agent possessing selective β-2 agonist-mediated vasodilation and β antagonism. Am J Cardiol. 1989;63(1):31–61. doi:10.1016/0002-9149(89)90120-3Sybertz EJ, Watkins RW. Preclinical pharmacologic properties of dilevalol, an antihypertensive agent possessing selective β-2 agonist-mediated vasodilation and β antagonism. Am J Cardiol. 1989;63(1):31–61. doi:10.1016/0002-9149(89)90120-3Carter BL. Labetolol. Drug Intell. Clin Pharm. 1983;17(10):704–712.Carter BL. Labetolol. Drug Intell. Clin Pharm. 1983;17(10):704–712.Kanto JH. Current status of laβlol, the first alpha- and β-blocking agent. Int J Clin Pharmacol Ther Toxicol. 1985;23 (11):617–628.Kanto JH. Current status of laβlol, the first alpha- and β-blocking agent. Int J Clin Pharmacol Ther Toxicol. 1985;23 (11):617–628.Louis WL, McNei JJ, Drummer OH. Pharmacology of combined alpha-β-blockade. Drugs. 1984;28(Suppl 2):16–34. doi:10.2165/00003495-198400282-00003Louis WL, McNei JJ, Drummer OH. Pharmacology of combined alpha-β-blockade. Drugs. 1984;28(Suppl 2):16–34. doi:10.2165/00003495-198400282-00003Sybertz EJ, Baum T, Pula KK, Nelson S, Eynon E, Sabin S. Studies on the mechanism of the acute antihypertensive and vasodilator actions of several β adrenoceptor. J Cardiovasc Pharmacol. 1982;4(5):749–758. doi:1097/00005344-198209000-00009Sybertz EJ, Baum T, Pula KK, Nelson S, Eynon E, Sabin S. Studies on the mechanism of the acute antihypertensive and vasodilator actions of several β adrenoceptor. J Cardiovasc Pharmacol. 1982;4(5):749–758. doi:1097/00005344-198209000-00009MacCarthy EP, Bloomfield SS. Laβlol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3(4):193–219. doi:10.1002/j.1875–9114.1983.tb03252MacCarthy EP, Bloomfield SS. Laβlol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3(4):193–219. doi:10.1002/j.1875–9114.1983.tb03252Franciosa JA, Freis ED. Normal cardiac output during β blockade with timolol in hypertensive patients. Clin Pharmacol Ther. 1975;18(2):158–164. doi:10.1002/cpt1975182158Franciosa JA, Freis ED. Normal cardiac output during β blockade with timolol in hypertensive patients. Clin Pharmacol Ther. 1975;18(2):158–164. doi:10.1002/cpt1975182158Lund-Johansen P, Ohm OJ. Haemodynamic long-term effects of metoprolol at rest and during exercise in essential hypertension. Br J Clin Pharmacol. 1977;4(2):147–151. doi:10.1111/j.1365–2125Lund-Johansen P, Ohm OJ. Haemodynamic long-term effects of metoprolol at rest and during exercise in essential hypertension. Br J Clin Pharmacol. 1977;4(2):147–151. doi:10.1111/j.1365–2125Morgan T, Snowden R, Butcher L. Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance. J Cardiovasc Pharmacol. 1987;11:124–129.Morgan T, Snowden R, Butcher L. Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance. J Cardiovasc Pharmacol. 1987;11:124–129.Trimarco B, Lembo G, DeLuca N, Ricciardelli B, Rosiello G, Volpe M et al. Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass. J Int Med Res. 1988;16(1):62A-72A.Trimarco B, Lembo G, DeLuca N, Ricciardelli B, Rosiello G, Volpe M et al. Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass. J Int Med Res. 1988;16(1):62A-72A.Prisant LM, Carr AA, Desnoyers M, Westcott RJ, Zinny MA, O’Donnell DM et al. Multicenter evaluation of the hemodynamic effects of bisoprolol in patients with mild to moderate hypertension. J Clin Pharmacol. 1990;30(12):1096–1111. doi:10.1002/j.1552–4604Prisant LM, Carr AA, Desnoyers M, Westcott RJ, Zinny MA, O’Donnell DM et al. Multicenter evaluation of the hemodynamic effects of bisoprolol in patients with mild to moderate hypertension. J Clin Pharmacol. 1990;30(12):1096–1111. doi:10.1002/j.1552–4604Trimarco B, Lembo G, DeLuca N, Ricciardelli B, Rosiello G, Volpe M et al. Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass. J Int Med Res. 1988;16(1):62A-72A.Trimarco B, Lembo G, DeLuca N, Ricciardelli B, Rosiello G, Volpe M et al. Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass. J Int Med Res. 1988;16(1):62A-72A.Prisant LM, Carr AA, Desnoyers M, Westcott RJ, Zinny MA, O’Donnell DM et al. Multicenter evaluation of the hemodynamic effects of bisoprolol in patients with mild to moderate hypertension. J Clin Pharmacol. 1990;30(12):1096–1111. doi:10.1002/j.1552-4604Prisant LM, Carr AA, Desnoyers M, Westcott RJ, Zinny MA, O’Donnell DM et al. Multicenter evaluation of the hemodynamic effects of bisoprolol in patients with mild to moderate hypertension. J Clin Pharmacol. 1990;30(12):1096–1111. doi:10.1002/j.1552-4604Педли Т. Гидродинамика крупных кровеносных сосудов. М.: Мир, 1983. 400 с.Pedley T. The fluid mechanics of large blood vessels. M.: Mir, 1983. 400 p. In Russian.Васюк Ю. А., Иванова С. В., Школьник Е. Л., Котовская Ю. В., Милягин В. А., Олейников В. Э. и др. Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике. Кардиоваск. тер. и профил. 2016;15(2). doi.org/10.15829/1728-8800-2016-2-4-19Vasyuk YA, Ivanova SV, Shkolnik EL, Kotovskaya YuV, Mishin VA, Oleyni kov VE et al. The agreed opinion of russian experts on the assessment of arterial stiffness in clinical practice. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2016;15(2). doi.org/10.15829/1728-8800-2016-2-4-19. In Russian.Xie H, Luo G, Zheng Y, Peng F, Xie L. A meta-analytical comparison of atenolol with angiotensin-converting enzyme inhibitors on arterial stiffness, peripheral blood pressure and heart rate in hypertensive patients. Clin Exp Hypertens. 2017;39(5):421– 426. doi:10.1080/10641963.2016.1267188Xie H, Luo G, Zheng Y, Peng F, Xie L. A meta-analytical comparison of atenolol with angiotensin-converting enzyme inhibitors on arterial stiffness, peripheral blood pressure and heart rate in hypertensive patients. Clin Exp Hypertens. 2017;39(5):421– 426. doi:10.1080/10641963.2016.1267188Niu W, Qi Y. A meta-analysis of randomized controlled trials assessing the impact of β-blockers on arterial stiffness, peripheral blood pressure and heart rate. Int J Cardiol. 2016;218:109–117. doi:10.1016/j.ijcard.2016.05.017Niu W, Qi Y. A meta-analysis of randomized controlled trials assessing the impact of β-blockers on arterial stiffness, peripheral blood pressure and heart rate. Int J Cardiol. 2016;218:109–117. doi:10.1016/j.ijcard.2016.05.017Stokes GS, Graham RM, Weber MA. The role of renin in the antihypertensive action of β adrenoreceptor blocking agents. Drugs. 1976;11(1):150–156. doi:10.2165/00003495-197600111-00031Stokes GS, Graham RM, Weber MA. The role of renin in the antihypertensive action of β adrenoreceptor blocking agents. Drugs. 1976;11(1):150–156. doi:10.2165/00003495-197600111-00031Stumpe KO, Kolloch R, Vetter H, Gramann W, Krück F, Ressel C et al. Acute and long-term studies of the mechanisms of action of β-blocking drugs in lowering blood pressure. Am J Med. 1976;60(6):853–865. doi:10.1016/0002-9343(76)90905-0Stumpe KO, Kolloch R, Vetter H, Gramann W, Krück F, Ressel C et al. Acute and long-term studies of the mechanisms of action of β-blocking drugs in lowering blood pressure. Am J Med. 1976;60(6):853–865. doi:10.1016/0002-9343(76)90905-0Saruta T, Eguchi T, Nakamura R, Misumi J, Kondo K, Oka M. Mechanism of renin inhibition by β adrenergic blocking agents. Effects of dl-, d-, l-propranolol and pindolol on renin release. Jap Heart J. 1980;21(1):103–109. doi:10.1536/ihj.21.103Saruta T, Eguchi T, Nakamura R, Misumi J, Kondo K, Oka M. Mechanism of renin inhibition by β adrenergic blocking agents. Effects of dl-, d-, l-propranolol and pindolol on renin release. Jap Heart J. 1980;21(1):103–109. doi:10.1536/ihj.21.103Vaile JC, Fletcher J, Al-Ani M, Ross HF, Littler WA, Coote JH et al. Use of opposing reflex stimuli and heart rate variability to examine the effects of lipophilic and hydrophilic β-blockers on human cardiac vagal control. Clin Sci (Lond). 1999;97(5):585–593.Vaile JC, Fletcher J, Al-Ani M, Ross HF, Littler WA, Coote JH et al. Use of opposing reflex stimuli and heart rate variability to examine the effects of lipophilic and hydrophilic β-blockers on human cardiac vagal control. Clin Sci (Lond). 1999;97(5):585–593.Wallin BG, Sundlöf G, Strömgren E, Aberg H. Sympathetic outflow to muscles during treatment of hypertension with metoprolol. Hypertension. 1984;6(4):557–562. doi:10.1161/01.hyp.6.4.557Wallin BG, Sundlöf G, Strömgren E, Aberg H. Sympathetic outflow to muscles during treatment of hypertension with metoprolol. Hypertension. 1984;6(4):557–562. doi:10.1161/01.hyp.6.4.557Tank J, Diedrich A, Schroeder C, Stoffels M, Franke G, Sharma AM et al. Limited effect of systemic β-blockade on sympa thetic outflow. J Hyperten. 2001;38(6):1377–1381. doi:10.1161/hy1201.096120Tank J, Diedrich A, Schroeder C, Stoffels M, Franke G, Sharma AM et al. Limited effect of systemic β-blockade on sympa thetic outflow. J Hyperten. 2001;38(6):1377–1381. doi:10.1161/hy1201.096120Burns J, David AS, Mary G, Mackintosh A, Stephen F, Ball G et al. Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive. Hypertension. 2004;44(4):454–458. doi:10.1161/01.HYP.0000141411.94596Burns J, David AS, Mary G, Mackintosh A, Stephen F, Ball G et al. Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive. Hypertension. 2004;44(4):454–458. doi:10.1161/01.HYP.0000141411.94596Coleman HA, Tare M, Parkington HC. Endothelial potassium channels, endothelium-dependent hyperpolarization and the regulation of vascular tone in health and disease. Clin Exp Pharmacol Physiol. 2004;31(9):641–649. doi:10.1111/j.1440-1681Coleman HA, Tare M, Parkington HC. Endothelial potassium channels, endothelium-dependent hyperpolarization and the regulation of vascular tone in health and disease. Clin Exp Pharmacol Physiol. 2004;31(9):641–649. doi:10.1111/j.1440-1681Dora KA, Gallagher NT, McNeish A, Garland CJ. Modulation of endothelial cell KCa3.1 channels during endotheliumderived hyperpolarizing factor signaling in mesenteric resistance arteries. Circ Res. 2008;102(10):1247–1255. doi:10.1161/CIRCRESAHA.108.172379Dora KA, Gallagher NT, McNeish A, Garland CJ. Modulation of endothelial cell KCa3.1 channels during endotheliumderived hyperpolarizing factor signaling in mesenteric resistance arteries. Circ Res. 2008;102(10):1247–1255. doi:10.1161/CIRCRESAHA.108.172379Félétou M. Calcium-activated potassium channels and endothelial dysfunction: therapeutic options? Br J Pharmacol. 2009;156(4):545–562. doi:10.1111/j.1476-5381Félétou M. Calcium-activated potassium channels and endothelial dysfunction: therapeutic options? Br J Pharmacol. 2009;156(4):545–562. doi:10.1111/j.1476-5381Garland CJ, Dora KA. EDH: endothelium-dependent hyperpolarization and microvascular signalling. Acta Physiol. (Oxf). 2017;219(1):152–161. doi:10.1111/apha.12649Garland CJ, Dora KA. EDH: endothelium-dependent hyperpolarization and microvascular signalling. Acta Physiol. (Oxf). 2017;219(1):152–161. doi:10.1111/apha.12649Harhun MI, Pucovský V, Povstyan OV, Gordienko DV, Bolton TB. Interstitial cells in the vasculature. J Cell Mol Med. 2005;9(2):232–243. doi:10.1111/j.1582-4934Harhun MI, Pucovský V, Povstyan OV, Gordienko DV, Bolton TB. Interstitial cells in the vasculature. J Cell Mol Med. 2005;9(2):232–243. doi:10.1111/j.1582-4934Yarova PL, Smirnov SV, Dora KA, Garland CJ. β1-Adrenoceptor associated dilatation in resistance arteries. Br J Pharmacol. 2013;169(4):875–886. doi:10.1111/bph.12160Yarova PL, Smirnov SV, Dora KA, Garland CJ. β1-Adrenoceptor associated dilatation in resistance arteries. Br J Pharmacol. 2013;169(4):875–886. doi:10.1111/bph.12160Cuesta AM, Albiñana V, Gallardo-Vara E, Recio-Poveda L, de Rojas PI, de Las Heras KVG et al. The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease. Sci Rep. 2019;9(1):10062. doi:10.1038/s41598-019-46448-6Cuesta AM, Albiñana V, Gallardo-Vara E, Recio-Poveda L, de Rojas PI, de Las Heras KVG et al. The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease. Sci Rep. 2019;9(1):10062. doi:10.1038/s41598-019-46448-6Yarova PL, Smirnov SV, Dora KA, Garland CJ. β1-Adrenoceptor stimulation suppresses endothelial IK(Ca)-channel hyperpolarization and associated dilatation in resistance arteries. Br J Pharmacol. 2013;169(4):875–886. doi:10.1111/bph.12160Yarova PL, Smirnov SV, Dora KA, Garland CJ. β1-Adrenoceptor stimulation suppresses endothelial IK(Ca)-channel hyperpolarization and associated dilatation in resistance arteries. Br J Pharmacol. 2013;169(4):875–886. doi:10.1111/bph.12160Setoguchi M, Ohya Y, Abe I, Fujishima M. Inhibitory action of betaxolol, a β-1-selective adrenoceptor antagonist, on voltage-dependent calcium channels in guinea-pig artery and vein. Br J Pharmacol. 1995;115(1):198–202. doi:10.1111/j.1476-5381Setoguchi M, Ohya Y, Abe I, Fujishima M. Inhibitory action of betaxolol, a β-1-selective adrenoceptor antagonist, on voltage-dependent calcium channels in guinea-pig artery and vein. Br J Pharmacol. 1995;115(1):198–202. doi:10.1111/j.1476-5381Yu DY, Su EN, Cringle SJ, Alder VA, Yu PK, DeSantis L. Systemic and ocular vascular roles of the antiglaucoma agents β-adrenergic antagonists and Ca2+ entry blockers. Surv Ophthalmol. 1999;43(1): S 214–S 222. doi:10.1016/s0039-6257(99)00042-9Yu DY, Su EN, Cringle SJ, Alder VA, Yu PK, DeSantis L. Systemic and ocular vascular roles of the antiglaucoma agents β-adrenergic antagonists and Ca2+ entry blockers. Surv Ophthalmol. 1999;43(1): S 214–S 222. doi:10.1016/s0039-6257(99)00042-9Dong Y, Ishikawa H, Wu Y, Shimizu K, Goseki T, Yoshitomi T. Effect and mechanism of betaxolol and timolol on vascular relaxation in isolated rabbit ciliary artery. Jap J Ophthalmol. 2006;50(6):504–508. doi:10.1007/s10384-006-0377-2Dong Y, Ishikawa H, Wu Y, Shimizu K, Goseki T, Yoshitomi T. Effect and mechanism of betaxolol and timolol on vascular relaxation in isolated rabbit ciliary artery. Jap J Ophthalmol. 2006;50(6):504–508. doi:10.1007/s10384-006-0377-2Priviero FB, Teixeira CE, Toque HA, Claudino MA, Webb RC, De Nucci G et al. Vasorelaxing effects of propranolol in rat aorta and mesenteric artery: a role for nitric oxide and calcium entry blockade. Clin Exp Pharmacol Physiol. 2006;33(5–6):448– 455. doi:10.1111/j.1440-1681Priviero FB, Teixeira CE, Toque HA, Claudino MA, Webb RC, De Nucci G et al. Vasorelaxing effects of propranolol in rat aorta and mesenteric artery: a role for nitric oxide and calcium entry blockade. Clin Exp Pharmacol Physiol. 2006;33(5–6):448– 455. doi:10.1111/j.1440-1681

The authors declare that there are no conflicts of interest present.